Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes
Diabetes eliminates the protective effect of female sex on the risk of coronary heart disease (CHD). The study assessed sex differences in the treatment of CHD risk factors among patients with diabetes.
A cross-sectional analysis included 3,849 patients with diabetes treated in five academic internal medicine practices from 2000 to 2003. Outcomes were stratified by the presence of CHD and included adjusted odds ratios (AORs) that women (relative to men) were treated with hypoglycemic, antihypertensive, lipid-lowering medications or aspirin (if indicated) and AORs of reaching target HbA1c, blood pressure, or lipid levels.
The results showed that women were less likely than men to have HbA1c <7% (without CHD: AOR 0.84 [95% CI 0.75–0.95], P = 0.005; with CHD: 0.63 [0.53–0.75], P < 0.0001). Women without CHD were less likely than men to be treated with lipid-lowering medication (0.82 [0.71–0.96], P = 0.01) or, when treated, to have LDL cholesterol levels <100 mg/dl (0.75 [0.62–0.93], P = 0.004) and were less likely than men to be prescribed aspirin (0.63 [0.55–0.72], P < 0.0001). Women with diabetes and CHD were less likely than men to be prescribed aspirin (0.70 [0.60–0.83], P < 0.0001) or, when treated for hypertension or hyperlipidemia, were less likely to have blood pressure levels <130/80 mmHg (0.75 [0.69–0.82], P < 0.0001) or LDL cholesterol levels <100 mg/dl (0.80 [0.68–0.94], P = 0.006).
From the results it was concluded that women with diabetes received less treatment for many modifiable CHD risk factors than diabetic men. More aggressive treatment of CHD risk factors in this population offers a specific target for improvement in diabetes care.
Diabetes Care 28:514-520, 2005
Obtain your patients’ A1C results when they’re most useful. in2it™ In-Office Analyzer delivers reimbursable, lab-accurate A1C test results when it truly matters—during a patient’s visit. Because its results are unaffected by Hb variants, in2it™ is an easy way to gauge the efficacy of your treatment strategies in less than seven minutes. CLIA waived (cleared for Prescription Home Use, and as a result has been CLIA waived). The in2it™ is available with flexible acquisition options. It’s your opportunity to keep your office’s A1C testing simple. So get the analyzer that makes both clinical and business sense. Get in2it™ For more information: Click Here
Do you tell your patients about Somogyi?
We want to know what you tell them.
Click here to send me an email